ZHX2 and breast carcinoma: We treated these two cell lines with hypoxia, the pan-prolyl hydroxylase inhibitor DMOG, or the proteasomal inhibitor MG132 and found that ZHX2 was upregulated by these treatments (Figure 1L, Figure 1—figure supplement 1E), further strengthening the conclusion that ZHX2 is regulated by pVHL for protein stability through potential prolyl hydroxylation in breast cancer.